GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Should l Buy VTRS?
Source: moomoo
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 14.010
Low
10.00
Averages
13.25
High
16.00
Current: 14.010
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
QSM Asset Management Initiates Position in Mobileye
- New Investment Position: According to an SEC filing dated April 15, 2026, QSM Asset Management initiated a new position in Mobileye Global Inc. by acquiring 611,003 shares during Q1 2026, with an estimated transaction value of $5.54 million, indicating confidence in the company's potential.
- Value Fluctuation: By the end of the quarter, the value of Mobileye's position was $4.13 million, reflecting price movements during the period and suggesting a cautious market sentiment regarding its future performance.
- Asset Allocation Insight: This new position constituted 2.02% of QSM's total reportable assets, highlighting the strategic diversification within the firm's investment portfolio, even as Mobileye's stock price has declined by 41.1% over the past year.
- Market Outlook Analysis: Despite facing significant market challenges, QSM's acquisition may signal an optimistic outlook for future profitability, particularly as autonomous driving technologies gain increasing importance in the automotive sector.
See More
QSM Asset Management Increases Stake in Mobileye
- Increased Holdings: QSM Asset Management acquired 611,003 shares of Mobileye in Q1 2026, with an estimated trade value of $5.54 million, reflecting confidence in the company's future prospects.
- Quarter-End Valuation: At quarter-end, the value of Mobileye's stake was $4.13 million, representing 2.02% of QSM's reportable assets under management, indicating its significance within the investment portfolio.
- Market Response: Despite Mobileye's stock being down over 80% from its all-time high, analysts project a forward P/E ratio of 30, suggesting the company is poised for profitability and rapid growth.
- Investment Timing: QSM's acquisition is viewed as a bullish signal in the current market climate, particularly as autonomous driving technology gains traction, potentially offering significant returns for investors.
See More
Viatris to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Viatris Inc. will report its Q1 2026 financial results on May 7, 2026, showcasing the company's performance and developments in the global healthcare sector.
- Webcast Conference: Company executives will host a webcast at 8:30 AM ET on the same day, allowing investors and the public to participate, thereby enhancing transparency and engagement.
- Replay Availability: A replay of the webcast will be available post-earnings release, ensuring that investors who cannot attend live can access key information, thus improving information accessibility.
- Company Mission and Vision: Viatris is committed to meeting global patient needs through innovation and resolute decision-making, demonstrating its strategic positioning and market impact within the pharmaceutical industry.
See More
Viatris Presents Four Studies at ASCRS Annual Meeting
- Research Presentation: Viatris will present four studies at the 2026 ASCRS Annual Meeting, including full results from the VEGA-3 Phase 3 study of MR-141, indicating its potential in treating presbyopia, which could enhance the company's position in the ophthalmology market.
- New Drug Research: The company will also showcase results from a Phase 1 study of varenicline nasal spray in healthy Japanese adults, demonstrating its potential application in improving visual function, which may open new market opportunities in the future.
- Visual Disturbance Analysis: An encore presentation of the LYNX-2 Phase 3 study highlights MR-142's effectiveness in improving visual disturbances under low-light conditions, emphasizing the drug's significance for post-refractive surgery patients and potentially strengthening Viatris's competitive edge in this area.
- Educational Support Initiative: Viatris provided independent funding for an educational symposium hosted by PRIME, aimed at fostering peer exchange and supporting the management of presbyopia, reflecting the company's commitment to advancing education and innovation in the ophthalmology field.
See More
VIATRIS INC.: BARCLAYS INCREASES TARGET PRICE FROM $15 TO $17
Company Announcement: Viasat Inc. has announced that Barclays has raised its price target for the company's stock.
New Price Target: The new price target for Viasat's stock is set at $17, an increase from the previous target of $15.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
QSM Asset Management Initiates Position in Mobileye
- New Investment Position: According to an SEC filing dated April 15, 2026, QSM Asset Management initiated a new position in Mobileye Global Inc. by acquiring 611,003 shares during Q1 2026, with an estimated transaction value of $5.54 million, indicating confidence in the company's potential.
- Value Fluctuation: By the end of the quarter, the value of Mobileye's position was $4.13 million, reflecting price movements during the period and suggesting a cautious market sentiment regarding its future performance.
- Asset Allocation Insight: This new position constituted 2.02% of QSM's total reportable assets, highlighting the strategic diversification within the firm's investment portfolio, even as Mobileye's stock price has declined by 41.1% over the past year.
- Market Outlook Analysis: Despite facing significant market challenges, QSM's acquisition may signal an optimistic outlook for future profitability, particularly as autonomous driving technologies gain increasing importance in the automotive sector.
See More
QSM Asset Management Increases Stake in Mobileye
- Increased Holdings: QSM Asset Management acquired 611,003 shares of Mobileye in Q1 2026, with an estimated trade value of $5.54 million, reflecting confidence in the company's future prospects.
- Quarter-End Valuation: At quarter-end, the value of Mobileye's stake was $4.13 million, representing 2.02% of QSM's reportable assets under management, indicating its significance within the investment portfolio.
- Market Response: Despite Mobileye's stock being down over 80% from its all-time high, analysts project a forward P/E ratio of 30, suggesting the company is poised for profitability and rapid growth.
- Investment Timing: QSM's acquisition is viewed as a bullish signal in the current market climate, particularly as autonomous driving technology gains traction, potentially offering significant returns for investors.
See More
Viatris to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Viatris Inc. will report its Q1 2026 financial results on May 7, 2026, showcasing the company's performance and developments in the global healthcare sector.
- Webcast Conference: Company executives will host a webcast at 8:30 AM ET on the same day, allowing investors and the public to participate, thereby enhancing transparency and engagement.
- Replay Availability: A replay of the webcast will be available post-earnings release, ensuring that investors who cannot attend live can access key information, thus improving information accessibility.
- Company Mission and Vision: Viatris is committed to meeting global patient needs through innovation and resolute decision-making, demonstrating its strategic positioning and market impact within the pharmaceutical industry.
See More
Viatris Presents Four Studies at ASCRS Annual Meeting
- Research Presentation: Viatris will present four studies at the 2026 ASCRS Annual Meeting, including full results from the VEGA-3 Phase 3 study of MR-141, indicating its potential in treating presbyopia, which could enhance the company's position in the ophthalmology market.
- New Drug Research: The company will also showcase results from a Phase 1 study of varenicline nasal spray in healthy Japanese adults, demonstrating its potential application in improving visual function, which may open new market opportunities in the future.
- Visual Disturbance Analysis: An encore presentation of the LYNX-2 Phase 3 study highlights MR-142's effectiveness in improving visual disturbances under low-light conditions, emphasizing the drug's significance for post-refractive surgery patients and potentially strengthening Viatris's competitive edge in this area.
- Educational Support Initiative: Viatris provided independent funding for an educational symposium hosted by PRIME, aimed at fostering peer exchange and supporting the management of presbyopia, reflecting the company's commitment to advancing education and innovation in the ophthalmology field.
See More
VIATRIS INC.: BARCLAYS INCREASES TARGET PRICE FROM $15 TO $17
Company Announcement: Viasat Inc. has announced that Barclays has raised its price target for the company's stock.
New Price Target: The new price target for Viasat's stock is set at $17, an increase from the previous target of $15.
See More
